2. Search Result
Search Result
Results for "

item/HY-B0011

" in MedChemExpress (MCE) Product Catalog:

36

阻害剤およびアゴニスト

3

スクリーニングライブラリ

1

ペプチド

4

天然物

3

同位体標識化合物

Targets Recommended:
製品番号 製品名 Target 研究分野 構造式
  • HY-B0011
    Docetaxel
    155+ Cited Publications

    RP-56976

    		 Microtubule/Tubulin Apoptosis Endogenous Metabolite Cancer
    Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .
    Docetaxel
  • HY-B0022
    Flutamide
    10+ Cited Publications

    SCH 13521

    		 Androgen Receptor Cancer
    Flutamide is an Androgen Receptor antagonist with Ki=55 nM. Flutamide inhibits prostate cancer progression and has synergistic effects with Docetaxel (HY-B0011). Flutamide also has the potential to protect against hyperthermia-induced multiple organ dysfunction syndrome .
    Flutamide
  • HY-132844
    Tunlametinib

    HL-085

    		 MEK Cancer
    Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC50=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) .
    Tunlametinib
  • HY-B0011A
    Docetaxel Trihydrate
    Maximum Cited Publications
    158 Publications Verification

    RP-56976 TriHYdrate

    		 Microtubule/Tubulin Apoptosis Cancer
    Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule depolymerization with an IC50 value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .
    Docetaxel Trihydrate
  • HY-B0018
    10-Acetyl docetaxel
    2 Publications Verification

    PNU-101383

    		 ADC Payload Cancer
    10-Acetyl docetaxel (PNU-101383) is an analog of Docetaxel (HY-B0011), with anticancer activity. 10-Acetyl docetaxel is a microtubule disassembly inhibitor, with antimitotic activity .
    10-Acetyl docetaxel
  • HY-115677
    ILK-IN-3

    		Ser/Thr Kinase Cancer
    ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model .
    ILK-IN-3
  • HY-B0011S
    Docetaxel-d9

    RP-56976-d9

    		 Microtubule/Tubulin Apoptosis Endogenous Metabolite Cancer
    Docetaxel-d9 is the deuterium labeled Docetaxel. Docetaxel (RP-56976) is a microtubule?depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of?bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .
    Docetaxel-d9
  • HY-176835
    PNR-3-80

    		Endonuclease Autophagy Cancer
    PNR-3-80 is an endonuclease G (ENDOG) inhibitor with an IC50 of 0.67 μM. As a non-competitive binder to the ENDOG-substrate complex, PNR-3-80 specifically inhibits the endonuclease activity of ENDOG. PNR-3-80 reduces cell death induced by Cisplatin (HY-17394) and Docetaxel (HY-B0011), and inhibits DNA damage and autophagy (autophagy) induced by Etoposide (HY-13629). PNR-3-80 can be used in studies related to cell injury .
    PNR-3-80
  • HY-12929
    NSC756093

    SU093

    		 Pim Apoptosis Cancer
    NSC756093 (SU093) is a GBP1:PIM1 interaction inhibitor. NSC756093 binds to GBP1-PIM1 with a Kd of 38 nM. NSC756093 suppresses proliferation, reduces migration, induces G1 phase cell-cycle arrest, and increases apoptotic cell death in ovarian cancer cells. NSC756093 reduces cellular proteasomal activity, induces accumulation of ubiquitinated proteins, and restrains tumor progression and lung metastasis in murine ovarian cancer xenograft models. NSC756093 increases sensitivity of prostate cancer cells to Docetaxel (HY-B0011) and sensitizes GBP1-overexpressing ovarian cancer cells to Paclitaxel (HY-B0015). NSC756093 can be used for the research of prostate cancer and ovarian cancer .
    NSC756093
  • HY-B0011R
    Docetaxel (Standard)

    RP-56976 (Standard)

    		 Reference Standards Microtubule/Tubulin Apoptosis Endogenous Metabolite Cancer
    Docetaxel (Standard) is the analytical standard of Docetaxel. This product is intended for research and analytical applications. Docetaxel (RP-56976) is a microtubule depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity .
    Docetaxel (Standard)
  • HY-W105318
    Pentabromophenol

    PBP

    		 TGF-beta/Smad Apoptosis Cancer
    Pentabromophenol (PBP) is a brominated flame retardant (BFR) widely used in various consumer products to reduce the flammability of materials used in different utility items. Pentabromophenol can accelerate the degradation of transforming growth factor-β (TGF-β) receptors by promoting clathrin-mediated endocytosis, thereby inhibiting the TGF-β signaling pathway. Additionally, Pentabromophenol can also induce apoptosis in peripheral blood mononuclear cells (PBMCs) .
    Pentabromophenol
  • HY-157942
    CYP1B1-IN-7

    		Cytochrome P450 Cancer
    CYP1B1-IN-7 (compound 2a) is a selective inhibitor of CYP1B1 (IC50: 75 nM). CYP1B1-IN-7 also reverses resistance (IC50: 29 μM) and exhibits cytotoxicity in the CYP1B1-overexpressing MCF-7 cell line that is resistant to Docetaxel (HY-B0011) .
    CYP1B1-IN-7
  • HY-W653942
    Docetaxel-d5

    RP-56976-d5

    		 Endogenous Metabolite Microtubule/Tubulin Apoptosis Isotope-Labeled Compounds Others
    Docetaxel-d5 is deuterium-labeled Docetaxel (HY-B0011) .
    Docetaxel-d5
  • HY-145525
    Linoleoyl-L-carnitine chloride

    CAR 18:2; C18:2 Carnitine; L-Carnitine linoleoyl ester

    		 Endogenous Metabolite Others
    Linoleoyl-L-carnitine is a naturally occurring long-chain acylcarnitine. Hepatic levels of linoleoyl-L-carnitine are increased following high-dose (200 mg/kg) administration of Isoniazid (Item No. 20378) in mice.
    Linoleoyl-L-carnitine chloride
  • HY-16676
    7-Epi-docetaxel

    4-epi-Docetaxel; 7-Epidocetaxel; 7-Epitaxotere

    		 Drug Metabolite Cytochrome P450 Cancer
    7-Epi-docetaxel (4-epi-Docetaxel; 7-Epidocetaxel; 7-Epitaxotere) is the major C7 epimeric impurity/in vivo metabolite of Docetaxel (HY-B0011). 7-Epi-docetaxel acts as a potent allosteric activator of rhCYP1B1. 7-Epi-docetaxel exhibits certain cell line-specific anti-migratory activity . 7-Epi-docetaxel can be used in research related to melanoma and lung adenocarcinoma .
    7-Epi-docetaxel
  • HY-137555
    11-dehydro-2,3-dinor Thromboxane B2

    11-deHYdro-2,3-dinor TXB2

    		 Endogenous Metabolite Metabolic Disease
    11-dehydro-2,3-dinor Thromboxane B2 (11-dehydro-2,3-dinor TXB2) is a metabolite of the TXA2 inactive metabolite TXB2 (Item No. 19030). It is formed from TXB2 by cytosolic aldehyde dehydrogenase (ALDH) and β-oxidation. Levels of 11-dehydro-2,3-dinor TXB2 are increased 5.2-fold in a surgery-induced rat model of tendon overuse.
    11-dehydro-2,3-dinor Thromboxane B2
  • HY-B0011AS
    Docetaxel-d5 trihydrate

    RP-56976-d5 triHYdrate

    		 Isotope-Labeled Compounds Microtubule/Tubulin Apoptosis Cancer
    Docetaxel-d5 (trihydrate) is the deuterium labeled Docetaxel (Trihydrate). Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC50 value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .
    Docetaxel-d5 trihydrate
  • HY-P10757
    DTX-P7

    		Peptide-Drug Conjugates (PDCs) Apoptosis HSP Eukaryotic Initiation Factor (eIF) PERK Cancer
    DTX-P7 is a peptide-drug conjugate. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90 .
    DTX-P7
  • HY-117404
    LLS30

    		MEK ERK Cancer
    LLS30 is an anticancer agent. LLS30 suppresses MEK/ERK pathway. LLS30 has anti-cancer effects against ovarian cancer, prostate cancer, and malignant peripheral nerve sheath tumors. LLS30 shows synergistic anti-cancer effect with Enzalutamide (HY-70002) or Docetaxel (HY-B0011) .
    LLS30
  • HY-W019939
    Hydroxy-PEG10-Boc

    		ADC Linker Cancer
    Hydroxy-PEG10-Boc is extacted from patent CN108707228 (example 0024) . Hydroxy-PEG10-Boc is a uncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Hydroxy-PEG10-Boc can be conjugated to Paclitaxel (HY-B0015) or docetaxel (HY-B0011) .
    Hydroxy-PEG10-Boc
  • HY-176780
    Gαi2-IN-1

    		Others Cancer
    Gαi2-IN-1 (Compound 14) is a Gαi2 inhibitor. Gαi2-IN-1 significantly inhibits cancer cells migration induced by the chemotherapeutic drug, such as Vorinostat (HY-10221) and Docetaxel (HY-B0011). Gαi2-IN-1 can be used for cancers like prostate, breast and ovarian cancer research .
    Gαi2-IN-1
  • HY-W114419
    Bisphenol C

    		Estrogen Receptor/ERR mTOR Cardiovascular Disease Metabolic Disease
    Bisphenol C is an estrogen receptor-α (ERα) agonist and an ERβ antagonist, with IC50 values of 2.65 nM for ERα and 1.94 nM for ERβ. Bisphenol C is a material of manufacturing polyester polymers like polycarbonate, is widely used in daily items like water bottles, food packaging, textile and so on .
    Bisphenol C
  • HY-B0011AR
    Docetaxel Trihydrate (Standard)

    RP-56976 TriHYdrate (Standard)

    		 Reference Standards Microtubule/Tubulin Apoptosis Cancer
    Docetaxel (Trihydrate) (Standard) is the analytical standard of Docetaxel (Trihydrate). This product is intended for research and analytical applications. Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC50 value of 0.2 μM . Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis .
    Docetaxel Trihydrate (Standard)
  • HY-W778546
    7-epi-10-Deacetyl baccatin III

    		Others Cancer
    7-epi-10-Deacetyl baccatin III can be isolated from the degradation impurities in Docetaxel (HY-B0011) .
    7-epi-10-Deacetyl baccatin III
  • HY-W778547
    7-epi-10-Oxo-10-deacetyl baccatin III

    10-DeHYdrobaccatin V

    		 Drug Intermediate Cancer
    7-epi-10-Oxo-10-deacetyl baccatin III (10-Dehydrobaccatin V) can be isolated from the degradation impurities in Docetaxel (HY-B0011) .
    7-epi-10-Oxo-10-deacetyl baccatin III
  • HY-13684
    Milataxel

    MAC-321

    		 Drug Derivative Microtubule/Tubulin Cancer
    Milataxel (MAC-321) is an orally active taxane analog of Docetaxel (HY-B0011). Milataxel enhances the rate of tubulin polymerization. Milataxel can be used in the research of colorectal cancer and non-small cell lung cancer .
    Milataxel
  • HY-136630
    Felotaxel

    SHR110008

    		 Drug Derivative Others
    Felotaxel (SHR110008) is a derivate of Docetaxel (HY-B0011), with antitumor activity and specific pharmacokinetic properties in rats. Felotaxel is rapidly distributed to normal tissues. The kidney is the major excretion organ, and its plasma protein binding capacity is nearly linearly related to concentration.
    Felotaxel
  • HY-116661
    Cannabigerovarin

    CBGV

    		 Cannabinoid Receptor Metabolic Disease
    Cannabigerovarin (CRM) (Item No. 29117) is a certified reference material categorized as a phytocannabinoid.1 This product is intended for research and forensic applications.
    Cannabigerovarin
  • HY-119001
    BKM1644

    		Survivin Cancer
    BKM1644, an acyl-tyrosine bisphosphonate amide derivative, exhibits potent anti-cancer activity. BKM1644 effectively inhibits the proliferation of metastatic, castration-resistant prostate cance (mCRPC) cells. BKM1644 sensitizes mCRPC cells to Docetaxel (HY-B0011) and retards the bone metastatic growth of prostate cance .
    BKM1644
  • HY-B0022R
    Flutamide (Standard)

    SCH 13521 (Standard)

    		 Reference Standards Androgen Receptor Cancer
    Flutamide (Standard) is the analytical standard of Flutamide. This product is intended for research and analytical applications. Flutamide is an Androgen Receptor antagonist with Ki=55 nM. Flutamide inhibits prostate cancer progression and has synergistic effects with Docetaxel (HY-B0011). Flutamide also has the potential to protect against hyperthermia-induced multiple organ dysfunction syndrome .
    Flutamide (Standard)
  • HY-130340
    Teicoplanin A3-1

    Teichomycin A3 factor 1; Antibiotic L 17054

    		 Antibiotic Infection
    Teicoplanin A3-1 is a degradation product of teicoplanins A2-1 to 5 (Item Nos. 20187, 20188, 20189, 20192). Teicoplanins are glycopeptide antibiotics produced by A. teichomyceticus that are broadly effective against Gram-positive bacteria in vitro.
    Teicoplanin A3-1
  • HY-124200
    AL 8810 isopropyl ester

    		Prostaglandin Receptor Endocrinology
    AL 8810 (Item No. 16735) is an 11β-fluoro analog of prostaglandin F2α which acts as a potent and selective antagonist at the FP receptor. AL 8810 isopropyl ester is a lipid soluble, esterified prodrug form of AL 8810 analogous to the commonly used therapeutic intraocular prostaglandin compounds such as Latanoprost (HY-B0577) and Travoprost (HY-B0584).
    AL 8810 isopropyl ester
  • HY-129303
    AP219

    		Endogenous Metabolite Metabolic Disease
    AP39 (Item No. 17100) is a compound used to increase the levels of hydrogen sulfide (H2S) within mitochondria. It consists of a mitochondria-targeting motif (triphenylphosphonium) coupled to an H2S-donating moiety (dithiolethione) by an aliphatic linker. AP219 is a control compound for AP39, containing the triphenylphosphonium scaffold but lacking the H2S-releasing portion.
    AP219
  • HY-134123
    Lipoxin B4 methyl ester

    LXB4 metHYl ester

    		 Drug Intermediate Leukotriene Receptor Metabolic Disease
    Lipoxin B4 (LXB4) methyl ester is a lipid soluble prodrug form of the transcellular metabolite LXB4. LXB4 is a positional isomer of LXA4 produced by the metabolism of 15-HETE or 15-HpETE by human leukocytes. At a concentration of 100 nM, LXB4 inhibits polymorphonuclear leukocyte (PMN) migration stimulated by leukotriene B4 (LTB4; Item No. 20110) and inhibits LTB4-induced adhesion of PMNs with an IC50 value of 0.3 nM.
    Lipoxin B4 methyl ester
  • HY-176781
    1-Deoxyceramide (m18:1/20:0)

    		Drug Derivative Neurological Disease
    1-Deoxyceramide (m18:1/20:0) is a type of ceramide. 1-Deoxyceramide (m18:1/20:0) is upregulated in the dorsal root ganglia of mice treated with Docetaxel (HY-B0011) .
    1-Deoxyceramide (m18:1/20:0)
  • HY-16457
    Simotaxel

    MST 997

    		 Microtubule/Tubulin Caspase Apoptosis Cancer
    Simotaxel (MST 997) is an orally active derivative of the taxane class. Simotaxel binds to β-tubulin and promotes tubulin polymerization (EC₅₀ = 0.9 μM), inhibits tubulin depolymerization, and causes cell cycle arrest at the G₂-M phase. Simotaxel disrupts the formation of the mitotic spindle and triggers the caspase-dependent apoptotic pathway (apoptosis). Simotaxel has inhibitory effects on Paclitaxel (HY-B0015) sensitive cell lines and overcomes drug resistance. Simotaxel can be used to study Paclitaxel / Docetaxel (HY-B0011) resistant solid tumors .
    Simotaxel

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: